Atti, Ana, Insalata, Ferdinando, Carr, Edward J, Otter, Ashley D, Castillo-Olivares, Javier, Wu, Mary, Harvey, Ruth, Howell, Michael, Chan, Andrew, Lyall, Jonathan, and others. (2022) Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study. Journal of Infection, 85 (5). pp. 545-556. ISSN 0163-4453. E-ISSN 1532-2742. (doi:10.1016/j.jinf.2022.09.004) (KAR id:96858)
PDF
Author's Accepted Manuscript
Language: English Restricted to Repository staff only DOI for this version: 10.22024/UniKent/01.02.96858.3276738
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Contact us about this Publication
|
|
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/3MB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.1016/j.jinf.2022.09.004 |
Abstract
Objectives: To investigate serological differences between SARS-CoV-2 reinfection cases and contemporary controls, to identify antibody correlates of protection against reinfection.
Methods: We performed a case-control study, comparing reinfection cases with singly infected individuals pre-vaccination, matched by gender, age, region and timing of first infection. Serum samples were tested for anti-SARS-CoV-2 spike (anti-S), anti-SARS-CoV-2 nucleocapsid (anti-N), live virus microneutralisation (LV-N) and pseudovirus microneutralisation (PV-N). Results were analysed using fixed effect linear regression and fitted into conditional logistic regression models.
Results: We identified 23 cases and 92 controls. First infections occurred before November 2020; reinfections occurred before February 2021, pre-vaccination. Anti-S levels, LV-N and PV-N titres were significantly lower among cases; no difference was found for anti-N levels. Increasing anti-S levels were associated with reduced risk of reinfection (OR 0•63, CI 0•47-0•85), but no association for anti-N levels (OR 0•88, CI 0•73-1•05). Titres >40 were correlated with protection against reinfection for LV-N Wuhan (OR 0•02, CI 0•001-0•31) and LV-N Alpha (OR 0•07, CI 0•009-0•62). For PV-N, titres >100 were associated with protection against Wuhan (OR 0•14, CI 0•03-0•64) and Alpha (0•06, CI 0•008-0•40).
Conclusions: Before vaccination, protection against SARS-CoV-2 reinfection was directly correlated with anti-S levels, PV-N and LV-N titres, but not with anti-N levels. Detectable LV-N titres were sufficient for protection, whilst PV-N titres >100 were required for a protective effect.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1016/j.jinf.2022.09.004 |
Projects: | 23196 |
Additional information: | For the purpose of open access, the author has applied a CC BY public copyright licence (where permitted by UKRI, an Open Government Licence or CC BY ND public copyright licence may be used instead) to any Author Accepted Manuscript version arising. |
Uncontrolled keywords: | SARS-CoV-2; Neutralising Antibodies; SARS-CoV-2 serology; Reinfection; Immunity |
Subjects: | Q Science > QR Microbiology > QR355 Virology |
Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
Funders: |
UK Health Security Agency (https://ror.org/018h10037)
Department of Health and Social Care (https://ror.org/03sbpja79) National Institute for Health Research (https://ror.org/0187kwz08) Medical Research Council (https://ror.org/03x94j517) |
Depositing User: | Nigel Temperton |
Date Deposited: | 11 Sep 2022 15:21 UTC |
Last Modified: | 05 Nov 2024 13:01 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/96858 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):